Skip to main content
. 2019 Feb 6;10(2):535–547. doi: 10.1007/s13300-019-0578-6

Table 4.

Different stage comparison of glucagon-stimulated C-peptide levels before and after ABM-MNC therapy

Items (months) Test for heterogeneity Analysis model Test for overall effect WMD or SMD 95% CI
I2 (%) P Z P
3 0 0.97 Fixed 0.71 0.48 − 0.11 (− 0.43, 0.20)
6 46 0.14 Fixed 2.00 0.05 0.48 (0.01, 0.95)
12 0 0.60 Fixed 3.36 < 0.001 0.91 (0.38,1.44)